Oncoral Pharma ApS initiates first human dosing on Herlev Hospital using a proprietary oral irinotecan product developed by Solural Pharma
Recent news
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
Career
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
career@soluralpharma.com for more information about available positions.